Related Experiment Video
Updated: Aug 7, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis
Amy Barton Pai1, Manjunath P Pai
1Department of Pharmacy and Nephrology, University of New Mexico College of Pharmacy, Albuquerque, NM 87131, USA. abpai@salud.unm.edu
Abstract:
Infections with gram-positive organisms are highly prevalent in hemodialysis patients and are a major cause of morbidity and mortality in this population. Antimicrobial therapy is widely used to treat these infections, and prolonged therapy with these agents is often necessary. Extensive use of antimicrobials in hemodialysis patients has resulted in a growing threat of resistance, especially among gram-positive bacteria such as Enterococcus spp and Staphylococcus aureus. Vancomycin-resistant enterococci and S. aureus isolates with reduced susceptibility to vancomycin are increasingly being reported in hemodialysis patients. Additionally, resistance of these organisms to newer agents, such as linezolid and daptomycin, has been documented. Appropriate utilization of antimicrobial therapy to treat these organisms requires an understanding of the pharmacokinetic and pharmacodynamic principles to optimize therapy and avoid adverse drug events. The pharmacokinetic and pharmacodynamic profile of antimicrobial agents can be significantly altered in patients with chronic kidney disease. This review will describe mechanisms of antimicrobial resistance among common gram-positive organisms. The pharmacokinetic and pharmacodynamic principles of cephalosporins, vancomycin, aminoglycosides, linezolid, and daptomycin and applications for use of these agents in the treatment of patients with bloodstream infections on hemodialysis are discussed.
Insights
Gram-positive infections are common in hemodialysis patients, leading to resistance against crucial antibiotics like vancomycin. Understanding antimicrobial pharmacokinetics is vital for effective treatment and avoiding side effects.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Gram-positive bacterial infections are a significant cause of illness and death in hemodialysis patients.
- Widespread antimicrobial use in this population has led to increasing resistance, particularly in Enterococcus spp. and Staphylococcus aureus.
- Emerging resistance to vancomycin and newer agents like linezolid and daptomycin poses a therapeutic challenge.
Purpose of the Study:
- To review mechanisms of antimicrobial resistance in common gram-positive organisms.
- To discuss pharmacokinetic and pharmacodynamic principles of key antimicrobial agents.
- To explore the application of these principles in treating bloodstream infections in hemodialysis patients.
Main Methods:
- Literature review focusing on antimicrobial resistance mechanisms.
- Analysis of pharmacokinetic and pharmacodynamic data for selected antibiotics.
- Discussion of clinical applications in hemodialysis patients.
Main Results:
- Gram-positive organisms, including Enterococcus spp. and Staphylococcus aureus, exhibit increasing resistance to vancomycin and newer antibiotics.
- Antimicrobial pharmacokinetics and pharmacodynamics are significantly altered in patients with chronic kidney disease.
- Understanding these altered profiles is crucial for optimizing treatment efficacy.
Conclusions:
- Antimicrobial resistance in gram-positive pathogens is a growing concern in hemodialysis.
- Tailoring antimicrobial therapy based on pharmacokinetic and pharmacodynamic principles is essential for effective treatment and minimizing adverse events.
- Further research and careful drug selection are needed to manage infections in this vulnerable patient group.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Kidney Injury V: Interprofessional Care
Hemodialysis III: Nursing Management
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations